JPWO2021155137A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021155137A5 JPWO2021155137A5 JP2022545976A JP2022545976A JPWO2021155137A5 JP WO2021155137 A5 JPWO2021155137 A5 JP WO2021155137A5 JP 2022545976 A JP2022545976 A JP 2022545976A JP 2022545976 A JP2022545976 A JP 2022545976A JP WO2021155137 A5 JPWO2021155137 A5 JP WO2021155137A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- capsid protein
- nucleic acid
- seq
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967416P | 2020-01-29 | 2020-01-29 | |
| US62/967,416 | 2020-01-29 | ||
| PCT/US2021/015695 WO2021155137A1 (en) | 2020-01-29 | 2021-01-29 | Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513004A JP2023513004A (ja) | 2023-03-30 |
| JP2023513004A5 JP2023513004A5 (https=) | 2024-02-02 |
| JPWO2021155137A5 true JPWO2021155137A5 (https=) | 2024-02-02 |
Family
ID=74673421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545976A Pending JP2023513004A (ja) | 2020-01-29 | 2021-01-29 | 眼科遺伝子療法のための改変されたアデノ随伴ウイルスカプシドタンパク質およびその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210261625A1 (https=) |
| EP (1) | EP4097121A1 (https=) |
| JP (1) | JP2023513004A (https=) |
| KR (1) | KR20220133941A (https=) |
| CN (1) | CN115989234A (https=) |
| AR (1) | AR121228A1 (https=) |
| AU (1) | AU2021213786A1 (https=) |
| BR (1) | BR112022014852A2 (https=) |
| CA (1) | CA3165019A1 (https=) |
| CO (1) | CO2022010227A2 (https=) |
| IL (1) | IL294868A (https=) |
| MX (1) | MX2022009252A (https=) |
| PH (1) | PH12022551878A1 (https=) |
| TW (1) | TW202142552A (https=) |
| WO (1) | WO2021155137A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024004217A (es) | 2021-10-08 | 2024-06-26 | Dyno Therapeutics Inc | Variantes de cápside y métodos de uso de estas. |
| EP4551253A1 (en) | 2022-07-08 | 2025-05-14 | Ospedale San Raffaele S.r.l. | Transgene cassettes |
| EP4303226A1 (en) | 2022-07-08 | 2024-01-10 | Ospedale San Raffaele S.r.l. | Transgene cassettes and epigenetic silencers for the treatment of disorders |
| KR102901502B1 (ko) | 2024-06-27 | 2025-12-18 | 이엔셀 주식회사 | 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU722624B2 (en) | 1996-09-06 | 2000-08-10 | Trustees Of The University Of Pennsylvania, The | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase |
| US6225291B1 (en) | 1997-04-21 | 2001-05-01 | University Of Florida | Rod opsin mRNA-specific ribozyme compositions and methods for the treatment of retinal diseases |
| US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| DE602004030327D1 (de) | 2003-05-21 | 2011-01-13 | Genzyme Corp | Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind |
| DK2191001T3 (en) | 2007-04-09 | 2016-09-19 | Univ Florida | RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF |
| US20100081707A1 (en) | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| HUE028341T2 (en) | 2009-06-16 | 2016-12-28 | Genzyme Corp | Improved methods for purification of recombinant aav vectors |
| EP2826860B1 (en) | 2010-04-23 | 2018-08-22 | University of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
| WO2012109570A1 (en) * | 2011-02-10 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| FI3628334T3 (fi) * | 2014-03-21 | 2023-09-15 | Genzyme Corp | Geenihoito verkkokalvon pigmenttirappeuma |
| IL248102B (en) * | 2014-05-02 | 2022-07-01 | Genzyme Corp | aav vectors for gene therapy of the central nervous system and retina |
| AU2015335923B2 (en) * | 2014-10-21 | 2021-04-29 | University Of Massachusetts | Recombinant AAV variants and uses thereof |
| NZ791267A (en) | 2016-08-15 | 2025-11-28 | Genzyme Corp | Methods for detecting AAV |
| US20190262373A1 (en) * | 2016-08-16 | 2019-08-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeted gene transfer |
| US12338267B2 (en) * | 2018-05-15 | 2025-06-24 | President And Fellows Of Harvard College | Viral vectors exhibiting improved gene delivery properties |
-
2021
- 2021-01-29 US US17/162,356 patent/US20210261625A1/en active Pending
- 2021-01-29 MX MX2022009252A patent/MX2022009252A/es unknown
- 2021-01-29 AU AU2021213786A patent/AU2021213786A1/en active Pending
- 2021-01-29 AR ARP210100248A patent/AR121228A1/es unknown
- 2021-01-29 PH PH1/2022/551878A patent/PH12022551878A1/en unknown
- 2021-01-29 TW TW110103551A patent/TW202142552A/zh unknown
- 2021-01-29 CA CA3165019A patent/CA3165019A1/en active Pending
- 2021-01-29 KR KR1020227029428A patent/KR20220133941A/ko active Pending
- 2021-01-29 CN CN202180011349.3A patent/CN115989234A/zh active Pending
- 2021-01-29 JP JP2022545976A patent/JP2023513004A/ja active Pending
- 2021-01-29 WO PCT/US2021/015695 patent/WO2021155137A1/en not_active Ceased
- 2021-01-29 EP EP21707556.3A patent/EP4097121A1/en active Pending
- 2021-01-29 BR BR112022014852A patent/BR112022014852A2/pt unknown
- 2021-01-29 IL IL294868A patent/IL294868A/en unknown
-
2022
- 2022-07-19 CO CONC2022/0010227A patent/CO2022010227A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022125201A (ja) | 変異体キャプシドを有するアデノ関連ウイルスビリオンおよびその使用方法 | |
| AU2019200949B2 (en) | High-transduction-efficiency raav vectors, compositions, and methods of use | |
| TWI848038B (zh) | 用於治療威爾森氏症之基因療法構築體 | |
| EP1828390B1 (en) | Chimeric vectors | |
| US9447433B2 (en) | Synthetic adeno-associated virus inverted terminal repeats | |
| CN110606874B (zh) | 用于基因转移到细胞、器官和组织中的变异aav和组合物、方法及用途 | |
| CN114981444B (zh) | Aav5的分离的修饰的vp1衣壳蛋白 | |
| CN118546217B (zh) | 靶向小梁网、角膜缘及rpe的aav衣壳蛋白及其应用 | |
| TW202440939A (zh) | 具心臟及骨骼肌特異性靶向模體的重組aav突變載體及含有其之組成物 | |
| JP2023522883A (ja) | 神経学的障害を処置するための組成物および方法 | |
| JPWO2021155137A5 (https=) | ||
| JP2022523050A (ja) | 合理的設計により増強された新規なａａｖウイルスによる網膜における高効率の形質導入および側方への広がり | |
| CN121013909A (zh) | 视网膜细胞中的基因表达的启动子及包含其的载体系统 | |
| CN117836312A (zh) | 分离的修饰的aav9衣壳蛋白vp1 | |
| EP4198047A1 (en) | Fukutin related protein gene transfer increase using modified itr sequences | |
| RU2825667C2 (ru) | Выделенный модифицированный белок VPI капсида аденоассоциированного вируса 9 серотипа (AAV9), капсид и вектор на его основе | |
| HK40075924A (en) | Isolated modified vp1 capsid protein of aav5 | |
| CN120738176A (zh) | 用于眼部基因治疗的增强子和启动子及其用途 | |
| JPWO2020154535A5 (https=) | ||
| CN112063625A (zh) | 编码arl2bp的核酸及其应用 | |
| JPWO2022115535A5 (https=) |